Table 3.
Patient distribution in treatment cohorts, Prev-AP FAS and New-AP CMD-set
| Cohorts Prev-AP, FAS (N = 642) | N (%) | |
|---|---|---|
| Prev-Olz | previous olanzapine monotherapy | 62 (9.7%) |
| Prev-Risp | previous risperidone monotherapy | 67 (10.4%) |
| Prev-Quet | previous quetiapine monotherapy | 49 (7.6%) |
| Prev-Atyp | previous other atypical antipsychotic monotherapy (amisulpride, aripiprazoleclozapine, ziprasidone, paliperidone) | 103 (16.0%) |
| Prev-Typ | previous typical antipsychotics | 90 (14.0%) |
| Prev-Comb | any previous combination therapy | 109 (17.0%) |
| Prev-None | not treated with antipsychotics within6 months prior to study entry | 162 (25.2%) |
| Cohorts New-AP, CMD-set (N = 476) | N (%) | |
| New-Olz | new olanzapine monotherapy | 206 (43.3%) |
| New-Risp | new risperidone monotherapy | 69 (14.5%) |
| New-Quet | new quetiapine monotherapy | 33 (6.9%) |
| New-Atyp | new other atypical antipsychotic monotherapy (amisulpride, aripiprazoleclozapine, ziprasidone, paliperidone) | 72 (15.1%) |
| New-Typ | new typical antipsychotic | 16 (3.4%) |
| New-Comb | new combination therapy (any combination) | 80 (16.8%) |
Abbreviations: CMD = complete metabolic data; FAS = full analysis set; New-AP = new antipsychotic treatment cohort; Prev-AP = previous antipsychotic treatment cohort;